Safety claims of new arthritis drugs may be misleading

May 30, 2002

Popular arthritis drugs, known as selective COX 2 inhibitors, may not be superior to traditional non-steroidal anti-inflammatory drugs, conclude researchers in this week's BMJ.

A study published in September 2000 concluded that the COX 2 inhibitor, celecoxib, was associated with a lower rate of stomach and intestinal ulcers than two older drugs for arthritis. However, only data for the first six months of the study were published. When all the data were considered, the published results appeared to be clearly flawed.

Two issues cause concern, say the researchers. The authors' explanations for these serious irregularities were inadequate, and the flawed findings published in the original article appear to be widely distributed and believed by many physicians.

They believe that an "industry independent" analysis of all trials of selective COX 2 inhibitors must be performed to include both published and unpublished data. They also call for the wide dissemination of the misleading results of the trial has to be counterbalanced by the equally wide dissemination of the findings of the reanalysis according to the original protocol.

"If this is not done, the pharmaceutical industry will feel no need to put the record straight in this or any future instances," they conclude.

The failure of this study may have more to do with the design of the trial than with inadequacies of COX 2 inhibitors, suggest researchers at Queen's Medical Centre, Nottingham in a second editorial. "Although it is extremely important to highlight distortion of information, it is equally important to recognise that the more information there is the more issues can arise, and a lack of information can easily nurture as many illusions as partial publication."
-end-


BMJ

Related Arthritis Articles from Brightsurf:

Physical activity and sleep in adults with arthritis
A new study published in Arthritis Care & Research has examined patterns of 24-hour physical activity and sleep among patients with rheumatoid arthritis, lupus, and knee osteoarthritis.

Is rheumatoid arthritis two different diseases?
While disease activity improves over time for most rheumatoid arthritis (RA) patients, long-term outcomes only improve in RA patients with autoantibodies, according to a new study published this week in PLOS Medicine by Xanthe Matthijssen of Leiden University Medical Center, Netherlands, and colleagues.

Does the Mediterranean diet protect against rheumatoid arthritis?
Previous research has demonstrated a variety of health benefits associated with the Mediterranean diet, which is rich in olive oil, cereals, fruit and vegetables, fish, and a moderate amount of dairy, meat, and wine.

Reducing corticosteroid use in rheumatoid arthritis
Is the long-term use of glucocorticoids essential in people with chronic inflammatory diseases such as rheumatoid arthritis, or can early discontinuation prevent characteristic side effects?

Psoriasis onset determines if psoriatic arthritis patients develop arthritis or psoriasis first
In a new study presented at the 2019 ACR/ARP Annual Meeting, researchers found the age of psoriasis onset determines whether arthritis or psoriasis starts first in people with psoriatic arthritis.

The ACR and the Arthritis Foundation present new guidelines offering therapeutic approaches and treatment options for juvenile idiopathic arthritis
Today, the American College of Rheumatology (ACR), in partnership with the Arthritis Foundation (AF), released two guidelines on juvenile idiopathic arthritis (JIA).

Does alcohol consumption have an effect on arthritis?
Several previous studies have demonstrated that moderate alcohol consumption is linked with less severe disease and better quality of life in patients with rheumatoid arthritis, but a new Arthritis Care & Research study suggests that this might not be because drinking alcohol is beneficial.

Prospect of a new treatment for rheumatoid arthritis
An international research group led by Charité -- Universitätsmedizin Berlin has completed testing a new drug to treat rheumatoid arthritis.

Can rare lymphocytes combat rheumatoid arthritis?
Immunologists at Friedrich-Alexander-Universität Erlangen-Nürnberg have demonstrated that ILC2, a group of rare lymphoid cells, play a key role in the development of inflammatory arthritis.

Which pain medication is safest for arthritis patients?
In a recent Alimentary Pharmacology & Therapeutics study, arthritis patients taking nonsteroidal anti-inflammatory drugs (NSAIDs) for pain plus a stomach acid-reducing medicine called esomeprazole had infrequent gastrointestinal side effects.

Read More: Arthritis News and Arthritis Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.